Gelteq Ltd (NASDAQ: GELS), a healthcare company focused on oral gel delivery technology, is drawing attention among traders — and its share structure tells a story of layered, variable-priced dilution overhang pressing against a genuinely small tradeable float.
The company has roughly 10 million shares outstanding. Only an estimated 4.4 million trade freely. Sitting behind that float are approximately 5.6 million shares of identified pending supply — convertible instruments, equity-line capacity, and warrants — meaning the overhang alone exceeds the current float by 27%.
The Equity Line
The largest single source of potential new shares is a $12 million equity line of credit — a standing agreement that lets the company sell stock on demand — executed in March 2025 with Lincoln Park Capital Fund. Under the deal, 4 million shares were registered for resale. The pricing formula is aggressive: Lincoln Park pays 95% of the lower of the day's lowest sale price and the average of the three lowest closing prices over the prior ten trading sessions — meaning every draw prices at or below the weakest recent prints.
A critical throttle applies. Because Gelteq's stock trades well below the $1.29 average-price threshold that would waive it, Nasdaq's Exchange Cap — a rule limiting below-market issuances to 19.99% of pre-deal shares without shareholder approval — binds the facility at 1,881,328 shares. That cap alone equals roughly 43% of the estimated float. Shareholder approval would unlock the full four-million-share registration.
Daily draws are capped at 25,000 shares per Regular Purchase. The agreement runs through March 2027.
The Convertible Notes
A second variable-priced channel compounds the picture. Notes issued in May 2024 totaling approximately AUD$1 million carry a 22% conversion discount to prevailing market — meaning the holder converts into shares priced 22% below wherever the stock happens to trade. There is no disclosed floor price. At recent levels, that discount implies an effective conversion price near $0.435 and roughly 1,494,000 new shares, equal to about 34% of the float.
This is a ratchet mechanism: a lower stock price mechanically produces more shares on conversion, which can push the stock lower still. The notes matured at the end of 2025 and no subsequent filing in the public record confirms whether they were settled in shares or cash.
Serial Financing History
Gelteq has conducted nine distinct capital events in approximately three years: shareholder loans, four separate convertible note tranches, a Nasdaq IPO in October 2024, the Lincoln Park equity line, a note-to-equity conversion, and the August 2025 resale registration. The company has never gone more than roughly six months without tapping a new funding source. Coupon rates on the notes escalated from 6% to 20% across vintages — a trajectory that signals pricing leverage shifting toward the funders.
Float Confidence
The 4.4-million-share float estimate itself carries low confidence. Standard market-data feeds anchor to a November 2024 share count and miss at least 175,000 commitment shares issued to Lincoln Park, roughly 249,700 shares from a March 2025 note conversion, and an unknown number of equity-line draws over approximately twelve months of unobserved activity. Real free-trading supply is very likely higher.
The sole bright spot in the overhang: 91,000 underwriter warrants struck at $5.00 are roughly 9x out of the money with no reset provision, making them structurally dormant. Meanwhile, the Lincoln Park agreement explicitly carves out one additional channel — an at-the-market facility, or ATM, through a registered broker-dealer — that the company could layer on top of the existing equity line at any time through March 2027.